Alterations of 3p21.31 tumor suppressor genes in head and neck squamous cell carcinoma: Correlation with progression and prognosis
Susmita Ghosh
Department of Oncogene Regulation, Chittaranjan National Cancer Institute, Kolkata, India
Search for more papers by this authorAmlan Ghosh
Department of Oncogene Regulation, Chittaranjan National Cancer Institute, Kolkata, India
Search for more papers by this authorGuru Prasad Maiti
Department of Oncogene Regulation, Chittaranjan National Cancer Institute, Kolkata, India
Search for more papers by this authorNeyaz Alam
Department of Surgery, Chittaranjan National Cancer Institute, Kolkata, India
Search for more papers by this authorBidyut Roy
Human Genetics Unit, Indian Statistical Institute, Kolkata, India
Search for more papers by this authorSusanta Roychoudhury
Molecular and Human Genetics and Genomic Division, Indian Institute of Chemical Biology, Kolkata, India
Search for more papers by this authorCorresponding Author
Chinmay Kumar Panda
Department of Oncogene Regulation, Chittaranjan National Cancer Institute, Kolkata, India
Fax: +91-33-2475-7606
Department of Oncogene Regulation, Chittaranjan National Cancer Institute, 37, SP, Mukherjee Road, Kolkata 700026, IndiaSearch for more papers by this authorSusmita Ghosh
Department of Oncogene Regulation, Chittaranjan National Cancer Institute, Kolkata, India
Search for more papers by this authorAmlan Ghosh
Department of Oncogene Regulation, Chittaranjan National Cancer Institute, Kolkata, India
Search for more papers by this authorGuru Prasad Maiti
Department of Oncogene Regulation, Chittaranjan National Cancer Institute, Kolkata, India
Search for more papers by this authorNeyaz Alam
Department of Surgery, Chittaranjan National Cancer Institute, Kolkata, India
Search for more papers by this authorBidyut Roy
Human Genetics Unit, Indian Statistical Institute, Kolkata, India
Search for more papers by this authorSusanta Roychoudhury
Molecular and Human Genetics and Genomic Division, Indian Institute of Chemical Biology, Kolkata, India
Search for more papers by this authorCorresponding Author
Chinmay Kumar Panda
Department of Oncogene Regulation, Chittaranjan National Cancer Institute, Kolkata, India
Fax: +91-33-2475-7606
Department of Oncogene Regulation, Chittaranjan National Cancer Institute, 37, SP, Mukherjee Road, Kolkata 700026, IndiaSearch for more papers by this authorAbstract
The aim of our study was to analyze the alterations of some candidate tumor suppressor genes (TSGs) viz. LIMD1, LTF, CDC25A, SCOTIN, RASSF1A and CACNA2D2 located in the chromosomal region 3p21.31 associated with the development of early dysplastic lesions of head and neck. In analysis of 72 dysplastic lesions and 116 squamous cell carcinoma of head and neck, both deletion and promoter methylation have been seen in these genes except for CDC25A and SCOTIN where no methylation has been detected. The alteration of LIMD1 was highest (50%) in the mild dysplastic lesions and did not change significantly during progression of tumor indicating its association with this stage of the disease. It was evident that alterations of LTF, CDC25A and CACNA2D2 were associated with development of moderate dysplastic lesions, while alterations in RASSF1A and CACNA2D2 were needed for progression. Novel somatic mutations were seen in exon 1 of LIMD1 (7%), intron 3/exon4 splice junction of LTF (2%) and exon 7 of cdc25A (10%). Quantitative RT-PCR analysis revealed mean reduced expression of the genes in the following order: LTF (67.6 ± 16.8) > LIMD1 (53.2 ± 20.1) > CACNA2D2 (23.7 ± 7.1) > RASSF1A (15.1 ± 5.6) > CDC25A (5.3 ± 2.3) > SCOTIN (0.58 ± 0.54). Immunohistochemical analysis of CDC25A showed its localization both in cytoplasm and nucleus in primary lesions and oral cancer cell lines. In absence of HPV infection, LTF and RASSF1A alterations jointly have adverse impact on survival of tobacco addicted patients. Thus, our data suggested that multiple candidate TSGs in the chromosomal 3p21.31 region were differentially associated with the early dysplastic lesions of head and neck. © 2008 Wiley-Liss, Inc.
Supporting Information
Additional Supporting Information may be found in the online version of this article.
| Filename | Description |
|---|---|
| IJC_23834_sm_suppinfo.doc256.5 KB | Supporting information Tables 1 to 6 and Figures 1 to 5 |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1 Tripathi A,Dasgupta S,Roy A,Sengupta A,Roy B,Roychudhury S,Panda CK. Sequential deletions in both arms of chromosome 9 are associated with the development of head and neck squamous cell carcinoma in Indian patients. J Exp Clin Cancer Res 2003; 22: 289–97.
- 2 Ha PK,Benoit NE,Yochem R,Sciubba J,Zahurak M,Sidransky D,Pevsner J,Westra WH,Califano J. A transcriptional progression model for head and neck cancer. Clin Cancer Res 2003; 9: 3058–64.
- 3 Uzawa N,Yoshida MA,Oshimaura M,Ikeuchi T. Suppression of tumorigenicity in three different cell lines of human oral squamous cell carcinoma by introduction of chromosome 3p via microcell mediated chromosome transfer. Oncogene 1995; 11: 1997–2004.
- 4 Perez-Ordonez BP,Beauchemin M,Jordan RC. Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol 2006; 59: 445–53.
- 5 Dasgupta S,Mukherjee N,Roy S,Roy A,Sengupta A,Roychowdhury S,Panda CK. Mapping of candidate tumor suppressor genes' loci on human chromosome 3 in head and neck squamous cell carcinoma of Indian patient population. Oral Oncol 2002; 38: 6–15.
- 6 Chakraborty SB,Dasgupta S,Roy A,Sengupta A,Roy B,Roychowdhury S,Panda CK. Differential deletions in 3p are associated with the development of head and neck squamous cell carcinoma from Indian patients. Cancer Genet Cytogenet 2003; 145: 1–9.
- 7 Ji L,Minna JD,Roth JA. 3p21.3 Tumor suppressor cluster: prospects for translational applications. Future Oncol 2005; 1: 79–92.
- 8 Pan ZG,Kashuba VI,Liu XQ,Shao JY,Zhang RH,Jiang JH,Guo C,Zabarovsky E,Ernberg I,Zeng YX. High frequency somatic mutations in rassf1A in nasopharyngeal carcinoma. Cancer Biol Ther 2005; 4: 1116–22.
- 9 Qiu GH,Tan LK,Loh KS,Lim CY,Srivastava G,Tsai ST,Tsao SW,Tao Q. The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma. Oncogene 2004; 23: 4793–806.
- 10 Hesson LB,Cooper WN,Latif F. Evaluation of the 3p21.3 tumor-suppressor gene cluster. Oncogene 2007; 26; 7283–301.
- 11 Frost GI,Mohapatra G,Wong TM,Csoka AB,Gray JW,Stern R. HYAL1LUCA-1, a candidate tumor suppressor gene on chromosome 3p21.3, is inactivated in head and neck squamous cell carcinomas by aberrant splicing of pre-mRNA. Oncogene 2000; 19: 870–8.
- 12 Gasparotto D,Maestro R,Piccinin S,Vukosavljevic T,Barzan L,Sulfaro SBoiocchi M. Overexpression of CDC25A and CDC25B in Head and Neck Cancers. Cancer Res 1997; 57: 2366–8.
- 13 Bourdon JC,Renzing J,Robertson PL,Fernandes KN,Lane DP. Scotin, a novel p53-inducible proapoptotic protein located in the ER and the nuclear membrane. J Cell Biol 2002; 158: 235–46.
- 14 Xiao Y,Monitto CL,Minhas KM,Sidransky D. Lactoferrin down-reguletes G1 Cyclin-dependent kinases during growth arrest of head and neck cancer cells. Clin Cancer Res 2004; 10: 8683–6.
- 15 MH Harmer, ed. UICC TNM classification of malignant tumors, 3rd edn. Geneva: Union Internationale Contre le Cancer (UICC), 1978.
- 16
Sambrook J,Fritsch EF,Maniatis T.
Molecular cloning: a laboratory manual,
2nd edn.
Cold Spring Harbor, NY:
Cold Spring Harbor Laboratory,
1989.
10.1111/j.1095-8312.1996.tb01434.x Google Scholar
- 17 Ichimura K,Bolin MB,Goike HM,Schmidt EE,Moshref A,Collins VP. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-s transition control gene abnormalities. Cancer Res 2000; 60: 417–24.
- 18 Loginov VI,Malyukova AV,Seryogin YA,Hodyrev DS,Kazubskaia TP,Ermilova VD,Garkavtseva RF,Kiselev LL,Zabarovsky ER,Braga EA. Methylation of the promoter region of the RASSF1A candidate tumor suppressor gene in primary epithelial tumors. Mol Biol 2004; 38: 654–67.
- 19 Ivanova T,Petrenko A,Gritsko T,Vinokourova S,Eshilev E,Kobzeva V,Kisseljov F,Kisseljova NP. Methylation and silencing of the retinoic acid receptor-β2 gene in cervical cancer. BMC Cancer. 2002; 2: 4.
- 20 Herman JG,Jeremy R,Graff JR,Myöhänen S,Nelkin BD,Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands Proc Natl Acad Sci USA 1996; 93: 9821–6.
- 21 Burbee DG,Forgacs E,Zöchbauer-Müller S,Shivakumar L,Fong K,Gao B,Randle D,Kondo M,Virmani A,Bader S,Sekido Y,Latif F, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001; 93: 691–9.
- 22 Tripathi A,Banerjee S,Chunder N,Roy A,Roychowdhury S,Panda CK. Differential alterations of the genes in the CDKN2A-CCND1-CDK4-RB1 pathway are associated with the development of head and neck squamous cell carcinoma in Indian patients. J Can Res Clin Oncol 2003; 129: 642–50.
- 23 Dallol A,Da Silva NF,Viacava P,Minna JD,Bieche I,Maher ER,Latif F. SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast Cancers. Cancer Res 2002; 62: 5874–80.
- 24 Livak KJ,Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods 2001; 25: 402–8.
- 25 Perrone F,Suardi S,Dagrada G,Bossi P,Locati L,Pilotti S. Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res 2006; 12: 6643–51.
- 26 Swan DC,Tucker RA,Tortolero-Luna G,Mitchell MF,Wideroff L,Unger ER,Nisenbaum RA,Reeves WC,Icenogle JP. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol 1999; 37: 1030–4.
- 27 Mao L,Lee DJ,Tockman MS,Erozan YS,Askin F,Sidransky D. Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci USA 1994; 91: 9871–5.
- 28 Kholodnyuk ID,Kozireva S,Kost-Alimova M,Kashuba V,Klein G Imreh S. Down regulation of 3p genes. LTF, SLC38A3 and. DRR1, upon growth of human chromosome 3-mouse fibrosarcoma hybrids in severe combined immunodeficiency mice. Int J Cancer 2006; 119: 99–107.
- 29 Angeloni D. Molecular analysis of deletions in human chromosome 3p21 and the role of resident cancer genes in disease. Brief Funct Genom Proteom 2007; 6: 19–39.
- 30 Kost-Alimova M,Imreh S. Modeling non-random deletions in cancer. Semin Cancer Biol 2007; 17: 19–30.
- 31 Senchenko VN,Liu J,Loginov W,Bazov I,Angeloni D,Seryogin Y,Ermilova V,Kazubskaya T,Garkavtseva R,Zabarovska VI,Kashuba VI,Kisselev LL, et al. Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas. Oncogene 2004; 23: 5719–28.
- 32 Imreh S,Klein G,Zabarovsky ER. Search for unknown tumor-antagonizing genes. Genes Chromosomes Cancer 2003; 38: 307–21.
- 33 Sharp TV,Munoz F,Darai E,Nicholson AG,Klein G,Imreh S,Boshoff C. LIM domains containing protein1 (LIMD1), a tumor suppressor encoded at chromosome 3p21.3, binds pRB and represses E2F-driven transcription. Proc Natl Acad Sci USA 2004; 101: 16531–6.
- 34 Iijima H,Tomizawa Y,Iwasaki Y,Sato K,Sunaga N,Dobashi K,Saito R,Nakajima T,Minna JD,Mori M. Genetic and epigenetic inactivation of LTF gene at 3p21.3 in lung cancers. Int J Cancer 2006; 118: 797–801.
- 35 Galaktionov K,Lee AK,Eckstein J,Draetta G,Meckler J,Loda M,Beach D. CDC25A phosphatases as potential human oncogenes. Science 1995; 269: 1575–7.
- 36 Wang Z,Wang M,Lazo JS,Carr BI. Identification of epidermal growth factor receptor as a target of Cdc25A protein phosphatase. J Biol Chem 2002; 77: 19470–5.
- 37 Dammann R,Schagdarsurengin U,Seidel C,Strunnikova M,Rastetter M,Baier K,Pfeifer GP. The tumor suppressor. RASSF1A in human carcinogenesis: an update. Histol Histopathol 2005; 20: 645–63.
- 38 Carboni GL,Gao B,Nishizaki M,Xu K,Minna JD,Roth JA,Ji L. CACNA2D2-mediated apoptosis in NSCLC cells is associated with alterations of the intracellular calcium signaling and disruption of mitochondria membrane integrity. Oncogene 2003; 22: 615–26.
- 39 Kulkarni V,Saranath D. Concurrent hypermethylation of multiple regulatory genes in chewing tobacco associated oral squamous cell carcinomas and adjacent normal tissues. Oral Oncol 2004; 40: 145–53.
- 40 Sengupta S,Chakrabarti S,Roy A,Panda CK,Roychoudhury S. Inactivation of hMLH1 and hMSH2 in HNSCC tumors and leukoplakia by promoter hypermethylation and its relation with MIN phenotype. Cancer 2007; 109: 703–12.
- 41 Huggins CJ,Gill M,Andrulis IL. Identification of rare variants in the hLIMD1 gene in breast cancer. Cancer Genet Cytogenet 2007; 178: 36–41.
- 42 Wegener S,Hampe W,Herrmann D,Schaller HC. Alternative splicing in the regulatory region of the human phosphatases CDC25A and CDC25C. Eur J Cell Biol 2000; 79: 810–15.
- 43 Dalal SN,Schweitzer CM,Gan J,DeCaprio JA. Cytoplasmic localization of human cdc25C during interphase requires an intact 14-3-3 binding site. Mol Cell Biol 1999; 19: 4465–79.
- 44 Yang J,Winkler K,Yoshida M,Kornbluth S. Maintenance of G2 arrest in the Xenopus oocyte: a role for 14-3-3-mediated inhibition of cdc25 nuclear import. EMBO J 1999; 18: 2174–83.
- 45 Agathanggelou A,Cooper WN,Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 2005; 65: 3497–508.
- 46 Feng Y,Zhao H,Luderer HF,Epple H,Ross FP,Teitelbaum SL,Longmore GD. The LIM protein, LIMD1, regulates AP-1 activation through an interaction with TRAF6 to influence osteoclast development. J Biol Chem 2006; 282: 39–48.
- 47 Tripathi A,Banerjee S,Chunder N,Roy A,Roychowdhury S,Panda CK. Differential alterations of the genes in the CDKN2A-CCND1-CDK4-RB1 pathway are associated with the development of head and neck squamous cell carcinoma in Indian patients. J Can Res Clin Oncol 2003; 129: 642–50.
- 48 Lerman MI,Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. Cancer Res 2000; 60: 6116–33.
- 49 Chow LS,Lo KW,Kwong J,To KF,Tsang KS,Lam CW,Dammann R,Huang DP. RASSF1A is a target tumor suppressor from 3p21 in nasopharyngeal carcinoma. Int J Cancer 2004; 109: 839–47.
- 50 Karlsson-Rosenthal C,Millar JB. Cdc25: mechanisms of checkpoint inhibition and recovery. Trends in Cell Biol 2006; 16: 285–92.
- 51 Boutros R,Lobjois V,Ducommun B. CDC25 phosphatases in cancer cells: key players? Good target? Nat Rev Cancer 2007; 7: 495–507.
- 52 Kristjansdottir K,Rudolph J. Cdc25 phosphatases and cancer. Chem Biol 2004; 11: 1043–51.
- 53 Dong SM,Sun D-II,Benoit NE,Kuzmin I,Lerman MI,Sidransky D. Epigenetic inactivation of RASSF1A in head and neck cancer. Clin Cancer Res 2003; 9 (10, Part 1): 3635–40.
- 54 Galaktionov K,Jessus C,Beach D. Raf1 interaction with cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation. Genes Dev 1995; 9: 1046–58.
- 55 Xia K,Lee RS,Nasimhan RP,Mukhopadhyay NK,Neel BG,Roberts TM. Tyrosine phosphorylation of the proto-oncoprotein Raf-1 is regulated by Raf-1 itself and the phosphatase Cdc25A. Mol Cell Biol 1999; 19: 4819–24.
- 56 Nemoto K,Vogt A,Oguri T,Lazo LS. Activation of the Raf-1/MEK/Erk kinase pathway by a novel Cdc25A inhibitor in human prostate cancer cells. Prostate 2004; 58: 95–102.
- 57 Conklin DS,Galaktionov K,Beach D. 14-3-3 proteins associate with cdc25 phosphatases. Proc Natl Acad Sci USA 1995; 92: 7892–6.
- 58 Weinberger PM,Yu Z,Haffty BG,Kowalski D,Harigopal M,Brandsma J,Sasaki C,Joe J,Camp RL,Rimm DL,Psyrri A. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006 10;24: 736–47.
Citing Literature
